Compare MEC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MEC | CTNM |
|---|---|---|
| Founded | 1945 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.4M | 480.5M |
| IPO Year | 2019 | 2024 |
| Metric | MEC | CTNM |
|---|---|---|
| Price | $21.64 | $12.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $24.33 | $19.00 |
| AVG Volume (30 Days) | 106.0K | ★ 248.6K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $8.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.99 | $3.35 |
| 52 Week High | $22.37 | $16.33 |
| Indicator | MEC | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 39.90 |
| Support Level | $17.20 | $11.54 |
| Resistance Level | $22.37 | $13.26 |
| Average True Range (ATR) | 0.89 | 0.62 |
| MACD | 0.22 | -0.03 |
| Stochastic Oscillator | 98.68 | 20.27 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, power sports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly and logistic services.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.